Advances in the drug clinical trials of neurofibromatosis type Ⅰ-associated plexiform neurofibromas
10.3760/cma.j.issn.1009-4598.2020.01.019
- VernacularTitle: Ⅰ型神经纤维瘤病相关丛状神经纤维瘤的药物临床试验进展
- Author:
Jieyi REN
1
;
Yihui GU
;
Qingfeng LI
;
Zhichao WANG
Author Information
1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
- Publication Type:Review
- Keywords:
Neurofibromatosis 1;
Neurofibroma, Plexiform;
Clinical trial;
Review
- From:
Chinese Journal of Plastic Surgery
2020;36(1):83-87
- CountryChina
- Language:Chinese
-
Abstract:
Neurofibromatosis type Ⅰ(NF1)is an autosomal dominant genetic disease triggered by mutations of nf1gene, nf1 gene and its encoded protein product neurofibromatoprotein play important roles in tumor supressive activity. Plexiform neurofibroma was the main manifestation among some patients For plexiform neurofibroma, surgical treatment did not have satisfactory effect. meanwhile, traditional radiotherapy and chemotherapy are ineffective. All of those above serve as challenges for clinical treatment and have been received much more attention from study of multimoics and targeting therapy In this Review, the clinical features of NF1-associated plexiform neurofibromasand, the progress regarding investigation of drug targets and clinical trials for the drug of plexiform neurofibroma will be presented.
